Coloplast A/S (OTCMKTS:CLPBY) Reaches New 52-Week Low – Should You Sell?

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY)’s share price hit a new 52-week low on Thursday . The company traded as low as $6.10 and last traded at $6.20, with a volume of 28664 shares trading hands. The stock had previously closed at $6.38.

Wall Street Analysts Forecast Growth

CLPBY has been the topic of a number of research reports. Sanford C. Bernstein raised shares of Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. Finally, The Goldman Sachs Group cut Coloplast A/S from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Coloplast A/S Trading Down 2.2%

The stock has a market cap of $14.06 billion, a PE ratio of 44.57, a price-to-earnings-growth ratio of 1.99 and a beta of 0.15. The company has a debt-to-equity ratio of 1.50, a quick ratio of 0.81 and a current ratio of 1.30. The company’s 50-day moving average price is $6.56 and its 200 day moving average price is $7.75.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. On average, sell-side analysts forecast that Coloplast A/S Sponsored ADR will post 0.4 EPS for the current fiscal year.

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.